There is no clinical evidence that sermorelin causes cancer. No studies have linked sermorelin use to tumor development in humans, and the medication was never pulled from the market for safety concerns. However, the honest answer is more nuanced than a simple “no,” because sermorelin works by raising growth hormone and IGF-1 levels, and elevated IGF-1 does play a role in how cancer cells grow and spread. Understanding that distinction is important.
What Sermorelin Actually Does in Your Body
Sermorelin is a synthetic version of a hormone your brain naturally produces called growth hormone-releasing hormone (GHRH). Rather than injecting growth hormone directly, sermorelin signals your pituitary gland to make and release more of its own growth hormone. That growth hormone then triggers your liver to produce IGF-1 (insulin-like growth factor 1), which is the compound that carries out most of the tissue-building, cell-regenerating effects people associate with growth hormone therapy.
This indirect mechanism is a key detail. Because sermorelin works through your body’s own feedback loops, the resulting IGF-1 increase tends to stay within a more physiological range compared to injecting synthetic growth hormone directly. Your pituitary has built-in limits on how much growth hormone it will release regardless of how much stimulation it receives, which acts as a natural ceiling.
The IGF-1 Connection to Cancer
The reason this question comes up at all is that IGF-1 has a well-documented relationship with cancer biology. IGF-1 binds to receptors on cells and activates signaling pathways that promote cell survival, growth, and division while simultaneously blocking the normal process of cell death. For healthy tissue, that’s useful. For cancerous cells, it can accelerate problems.
Research in animal models illustrates just how powerful this effect can be. Transgenic mice engineered to overproduce IGF-1 in skin cells developed tumors at seven times the rate of normal mice after exposure to a carcinogen. Mice overproducing IGF-1 in prostate tissue developed abnormal cell growth by two to three months of age, and 50% had prostate tumors by six months. These are extreme examples of sustained, localized IGF-1 overproduction far beyond what sermorelin therapy would produce, but they demonstrate the biological mechanism clearly.
IGF-1 doesn’t just help cancer cells multiply. It promotes the formation of new blood vessels that tumors need to grow, helps cancer cells become mobile and invasive by reorganizing their internal structure, and triggers the release of enzymes that dissolve surrounding tissue to clear a path for spreading cells. Laboratory studies have also shown that elevated IGF-1 signaling can make cancer cells more resistant to treatment.
To be clear: none of this means IGF-1 initiates cancer from scratch. The concern is that if cancerous or precancerous cells already exist in your body, higher IGF-1 levels could help them grow faster or spread more readily.
Why Sermorelin Differs From Direct Growth Hormone
When people inject recombinant human growth hormone (rhGH) directly, they bypass the pituitary’s regulatory controls entirely. This can create sharp spikes in both growth hormone and IGF-1. Sermorelin, by contrast, relies on the pituitary to do the work, which means the hormonal response is more gradual and self-limiting.
There’s another important nuance. Growth hormone stimulates your liver to produce not only IGF-1 but also a binding protein called IGFBP-3. This binding protein latches onto circulating IGF-1 and reduces the amount of free IGF-1 available to interact with cell receptors. IGFBP-3 can also independently promote cancer cell death. So when growth hormone levels rise through a natural pathway, the simultaneous increase in this binding protein may partially offset the cancer-related risks of higher IGF-1. Researchers studying prostate cancer risk with growth hormone therapy have noted that the ratio between IGF-1 and IGFBP-3 matters more than either number alone.
Clinical guidelines for adult growth hormone therapy recommend keeping IGF-1 levels in the mid-normal range for the patient’s age and sex rather than pushing them to the upper end. This principle applies equally to sermorelin therapy, where periodic blood monitoring helps ensure levels stay within safe bounds.
What the Clinical Evidence Shows
Sermorelin was FDA-approved as an orphan drug for treating growth hormone deficiency in children with growth failure. It was also designated for AIDS-related wasting and as a fertility treatment adjunct, though those indications were later withdrawn for reasons unrelated to safety. At no point was sermorelin removed from the market due to safety or efficacy concerns.
The medication is generally well tolerated in clinical use. Some preliminary research has even explored whether it could benefit people with certain recurrent brain tumors, which would be a counterintuitive application if sermorelin itself promoted cancer growth.
That said, the available evidence has a significant gap. A 2017 review of growth hormone secretagogues (the drug class sermorelin belongs to) noted that no safety data examining malignancy and mortality rates currently exist for these compounds with long-term use. The review explicitly called for studies evaluating cancer incidence over extended treatment periods. This means we can say sermorelin hasn’t been shown to cause cancer, but we can’t say it’s been rigorously proven safe on that front either. The long-term data simply hasn’t been collected.
Who Should Be Cautious
The theoretical concern about IGF-1 and cancer cell growth has practical implications for certain people. If you have an active cancer diagnosis, a history of cancer, or known precancerous conditions, raising your IGF-1 levels through any means carries a risk that isn’t well quantified. Most clinicians will avoid prescribing sermorelin or any growth hormone-stimulating therapy in these situations.
For people without a cancer history, the risk profile looks different. Your body already produces IGF-1 naturally, and sermorelin nudges those levels higher within a physiological range rather than flooding your system. The animal studies showing dramatic tumor promotion involved IGF-1 concentrations far above what you’d see with therapeutic sermorelin use. Still, if you’re considering long-term use, periodic monitoring of IGF-1 levels is a reasonable precaution to ensure they remain in the mid-normal range rather than climbing to the upper end, where population-level studies have suggested modestly higher cancer risk.